Osteosarcopenia — A New Risk Factor for Mortality After TAVR

The combination of low muscle mass and bone density was associated with a threefold increase in 1-year mortality risk.

Frailty is a recognized risk factor for mortality and morbidity after surgical or transcatheter aortic valve replacement (TAVR). To better refine this risk and improve prognostic modeling for patients with severe aortic stenosis referred for TAVR, investigators examined the association of osteosarcopenia — the concomitant presence of low bone density and low muscle mass — with post-TAVR mortality. Osteosarcopenia was assessed on the pre-TAVR computed tomography scan by measuring vertebral bone density and psoas muscle mass.

This post hoc analysis of a prospective cohort study included 605 patients aged ≥70 years undergoing TAVR (mean age, 83 years; 45% women). Patients with osteosarcopenia were older, more likely to be men, and more likely t…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)